Hosted on MSN

Diagnosed with late-onset Pompe disease (LOPD) — what should I do now?

Late-onset Pompe disease (LOPD) is a rare genetic disorder that causes glycogen buildup in muscle tissue, resulting in ...
Everyday Health on MSN

How to preserve your independence with late-onset Pompe disease (LOPD)

Learn how to maintain your independence with this rare genetic disorder through adaptive tools, exercise, home modifications, and specialized diet tips.

Aro Biotherapeutics Reports Positive Phase 1b Topline Results for ABX1100, a Muscle-targeted GYS1 siRNA, in Patients with Late-Onset Pompe Disease (LOPD)

Aro Reports Positive Phase 1b Topline Results for ABX1100, a Muscle-targeted GYS1 siRNA, in Patients with Late-Onset Pompe ...
Seeking Alpha

Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease

WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc (DYN). (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics ...
WebMD

Managing Late-Onset Pompe Disease With Opfolda

Opfolda (miglustat) is a medicine taken with another medicine for certain people with late-onset Pompe disease. Pompe disease is a rare genetic disorder that is caused by an abnormal gene for a ...
Morningstar

Aro Biotherapeutics Reports Preliminary Efficacy for ABX1100, a Muscle-targeted GYS1 siRNA, in Patients with Late-Onset Pompe Disease (LOPD)

Aro Biotherapeutics, a clinical-stage biotechnology company developing potent and tissue-targeted short-interfering RNA (siRNA) medicines, today announced interim data from a phase 1b study of ABX1100 ...
Morningstar

Aro Biotherapeutics Reports Positive Phase 1b Topline Results for ABX1100, a Muscle-targeted GYS1 siRNA, in Patients with Late-Onset Pompe Disease (LOPD)

Phase 1b data to inform continued development of ABX1100 as a potential therapeutic in LOPD Aro Biotherapeutics, a clinical-stage biotechnology company developing potent and tissue-targeted ...